CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Translated title of the contribution: CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

T.O. Bergmeijer, P.W.A. Janssen, J.C. Schipper, K. Qaderdan, M. Ishak, R.S. Ruitenbeek, F.W. Asselbergs, A.W. van 't Hof, W.J.M. Dewilde, F. Spanó, J.P.R. Herrman, J.C. Kelder, M.J. Postma, A. de Boer, V.H.M. Deneer, J.M. ten Berg

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionCYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
Original languageUndefined/Unknown
Pages (from-to)16-22
Number of pages7
JournalAmerican Heart Journal
Volume168
Publication statusPublished - 2014

Cite this